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Acid-sensing ion channels (ASICs) are activated by extracellular pH fluctuations to play critical 
roles in normal brain functions. They also contribute to brain damage following ischemic stroke 
when blood flow is cut off from parts of the brain causing the extracellular pH to drop. Inhibiting 
ASIC1a in animal models of ischemia prevents much of this permanent brain damage, 
implicating ASIC1a as a novel therapeutic target. Surprisingly, little is known about the 
mechanism of ASIC-mediated cell death, and there are currently no drugs to specifically inhibit 
ASIC1a in patients. The Askwith lab has found that activation of the delta opioid receptor (DOR) 
in neuronal cultures attenuates ASIC-mediated cell death. Further, the prominent hypothesis on 
the mechanism of DOR-induced neuroprotection involves interference with the association 
between ASIC1a and the Receptor Interacting Protein Kinase 1 (RIP1) and RIP1 
phosphorylation. The purpose of this study is to optimize a method to quantify ASIC-mediated 
cell death in hippocampal slices subjected to oxygen-glucose deprivation (OGD) in order to 
mimic cerebral ischemia more accurately than in cell culture and test the molecular hypothesis 
on this novel mechanism of neuroprotection. In order to attain this goal, we treated mouse acute 
hippocampal slices with either OGD or control conditions then stained cells to quantify death. 
Results showed increased cell death following OGD treatment relative to the control. 
Intervention of this model with DOR activation via SNC80 during the OGD period showed 
attenuation of ASIC-mediated cell death, implicating DOR activation as a novel target for the 
regulation of this cell death pathway. Cell death was also reduced by inhibition of RIP1 via 
necrostatin-1, suggesting that the mechanism of this cell death is dependent on RIP1 activity. 
These data indicate that our model replicates observations from neuronal culture and that this 
system is a useful model to study ASIC-mediated cell death.  
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Chapter 1: Introduction 
Acid-sensing ion channels (ASICs) function as proton-gated channels and post-synaptic 
receptors that are essential for normal brain functions including fear, synaptic plasticity, memory 
(Du et al., 2014; Wemmie et al., 2003), and retinal function (Ettaiche et al., 2006). In addition to 
their involvement in normal physiological activity, they are also key players in a variety of other 
situations involving pH fluctuations including anxiety (Pidoplichko et al., 2014), addictive 
behaviors (Kreple et al., 2014), depression (Coryell et al., 2009), seizure termination (Ziemann et 
al., 2008), and pain (Bohlen et al., 2011; Diochot et al., 2012). A critical role of acid-sensing ion 
channels more closely examined in this thesis is their contribution to neuronal death and brain 
damage following cerebral acidosis as in ischemic stroke (Chu et al., 2013; Siesjo, 1988; Xiong 
et al., 2004, 2008; Yang et al., 2011). During an ischemic stroke, blood flow is cut off from parts 
of the brain causing the pH to drop and activating ASIC1a (Chu et al., 2013; Kagansky et al., 
2001; Xiong et al., 2004, 2008; Yang et al., 2011). When ASIC1a is inhibited following an 
ischemic event in animal models, much of the cell death is prevented (Xiong et al., 2004; Yang 
et al., 2011). Thus, ASIC1a represents a potential therapeutic target to prevent permanent brain 
damage following stroke. My thesis addresses ASIC-dependent cell death and the development 
of an in vitro model to quantify this cell death in mouse hippocampal slices subjected to oxygen-
glucose deprivation (OGD), a condition mimicking cerebral ischemia in the acute brain slice. In 
addition to addressing the development and optimization of this model, my thesis examines its 
utilization to study neuroprotective strategies targeting ASIC-mediated cell death inhibition as 
well as the mechanism involved. 
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Acid-sensing ion channels were first discovered by Krishtal and Pidoplichko in 1980 
when they found that neurons in the rat trigeminal and spinal ganglia displayed an inward cation 
current in response to a decrease in pH (Krishtal and Pidoplichko, 1980). In 1997, ASICs were 
cloned for the first time by Waldmann et al. and characterized as a member of the epithelial 
sodium channel/degenerin family of ion channels (Waldmann et al., 1997). Although first 
isolated in specific ganglia, it is now known that ASICs are expressed ubiquitously throughout 
the central and peripheral nervous systems with high levels of expression in the dorsal root 
ganglia, olfactory bulbs, hippocampus, amygdala, cerebellum, and cerebral cortex (Waldmann 
and Lazdunski, 1998). Four genes encode seven known ASIC subunits, including ASIC 1a, 1b1, 
1b2, 2a, 2b, 3 and 4 (Chu and Xiong, 2012), which can form heteromeric or homomeric trimers 
with varying kinetics, pH sensitivities, locations, and functions (Escoubas et al., 2000). For 
instance, ASIC1a can be found in the brain and sensory neurons, ASIC2a is found mostly in the 
brain, and ASIC3 is found only in nociceptors (Escoubas et al., 2000), whereas ASIC4 is found 
in heterotrimers with other ASIC subunits in certain brain regions as well as in the pituitary 
gland (Kellenberger and Schild, 2002). Thus, ASICs are widespread channels highly expressed 
throughout the nervous system. 
Structurally, all ASIC subunits are comprised of two transmembrane domains, a long 
extracellular loop containing several conserved cysteines, and shorter N- and C- termini on the 
intracellular surface (Chu and Xiong, 2012). ASICs are gated by protons and activated by low 
pH. Upon activation, the channels open to allow cation influx and are most permeable to Na+, 
although they also display some permeability to Li+, K+, Ca2+, and H+ (Waldmann et al., 1997). 
Under normal circumstances, it is thought that ASICs are activated during synaptic transmission 
when synaptic vesicles release protons and lower the pH in the synapse (Du et al., 2014; Kreple 
5 
 
et al., 2014). In the presence of protons, or acidic pH, ASICs are activated and produce transient 
current (Vick and Askwith, 2015). The pH level needed to activate ASICs varies depending on 
the ASIC subunits making up the channel (Vick and Askwith, 2015), however ASICs are known 
to be capable of activation at pH 6.7 and below. In conditions when the pH is lower than 
physiological pH but not low enough to activate ASICs, the channel enters a state called steady 
state desensitization (Escoubas et al., 2000) and cannot open even if the pH continues to drop, 
which is important to the channel’s normal function and ability to respond to rapid pH changes at 
the synapse (Vick and Askwith, 2015). Additionally, although ASICs are gated by protons, they 
can be affected by toxins (Vick and Askwith, 2015), and they are also normally modulated by 
neuropeptides, found after neurotransmitter release in the synaptic cleft (Vick and Askwith, 
2015). Some of these neuropeptides slow inactivation and produce a sustained current or 
decrease the proton sensitivity of steady state desensitization (Askwith et al., 2000). Thus, the 
structure and normal molecular activity of ASICs are characterized and can be manipulated 
pharmacologically. 
Interestingly, much of this physiological activity as well as behavior are altered by 
knocking out ASIC genes in mice. ASIC knockout mice were produced for the study of ASIC 
activity using a technique which takes advantage of homologous recombination in embryonic 
stem cells. In this process, a replacement vector was developed containing a gene yielding 
neomycin resistance flanked by regions of homologous DNA that normally flank the ASIC1 
gene (Hall et al., 2009). The vector was transfected into embryonic stem cells from a mouse 
blastocyst in vitro, and homologous recombination was allowed to occur in order to replace the 
ASIC1 gene in the chromosomes of the stem cells with the neomycin resistance gene (Hall et al., 
2009). These stem cells were injected into a mouse blastocyst and implanted into the uterus of a 
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mouse to obtain chimeric mice made up of some cells derived from the host blastocyst and some 
from the stem cells (Hall et al., 2009). Chimeric mice possessing reproductive cells with the 
ASIC1 gene knocked out were bred with wildtype mice to obtain mice heterozygous for the 
ASIC1 gene, which were bred to obtain homozygous knockout mice no longer possessing the 
ASIC1 gene in any of their cells (Hall et al., 2009). These mice have been used for the vast 
majority of studies assessing the many roles of ASICs in the nervous system. 
The creation of mice genetically lacking ASIC genes has been invaluable for determining 
what ASICs do physiologically and how they contribute to pathological situations. For instance, 
it was discovered that knocking out the ASIC1 gene yields a loss of current in central neurons 
above pH 5 as well as problems in behaviors related to anxiety, panic, depression, and fear (Vick 
and Askwith, 2015). Associated with fear behaviors, learning, memory, and synaptic plasticity 
have been shown to be impaired in ASIC knockout mice as well (Wemmie et al., 2002). A study 
using high frequency stimulation found impaired long term potentiation in ASIC knockout mice 
(Wemmie et al., 2002). Deficits in ASIC knockout mice were also discovered with spatial 
learning and memory as well as with associative learning, using the hidden platform version of 
the Morris water maze and classical eyeblink conditioning, respectively (Wemmie et al., 2002). 
In contrast, studies examining cocaine-conditioned place preference in ASIC1a knockout mice 
and cocaine self-administration suggest that ASIC1a in the nucleus accumbens negatively 
regulates learning and memory associated with drug use as well as plasticity associated with 
addiction (Kreple et al., 2014). Such studies have indicated important physiological roles for 
ASICs in the nervous system and characterized the effects of removing them. 
Additionally, ASIC1a has been implicated in modulation of innate fear processes 
(Coryell et al., 2007). A series of studies with mice lacking the ASIC1a gene showed reduced 
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fear behavior relative to ASIC wildtype mice in the open field test as well as reduced 
unconditioned acoustic startle response and reduced freezing in response to predator odor TMT 
(Coryell et al., 2007). Further, reduced current in amygdala neurons from ASIC1 knockout mice 
following acidosis implicates ASIC1 in learned fear (Wemmie et al., 2003). Investigating ASIC 
involvement in learned fear behaviors associated with the amygdala using an auditory fear 
conditioning test showed that ASIC1 knockout mice display decreased fear behavior related to 
cue and context fear conditioning (Wemmie et al., 2003). Thus, the use of ASIC knockout mice 
has been crucial in the discovery and characterization of the involvement of ASIC1 in fear, 
among other important normal brain functions. 
Critically, in addition to carrying out key physiological functions, ASIC activity has been 
shown to play a role in degeneration and cell death following cerebral acidosis. Throughout the 
nervous system, ASICs are activated by small pH changes that occur with neurotransmitter 
release to perform their physiological functions (Du et al., 2014; Kreple et al., 2014). However, 
ASIC1a-induced neurological injury results when pH is reduced in the brain over a long period 
of time, which occurs in many neurological disorders and neurodegenerative diseases. In 
ischemic stroke, oxygen supply is cut off from the brain tissue, lowering glucose levels as well as 
the pH to as low as pH 6.0 (Kagansky et al., 2001). This pH reduction is largely a result of 
increased anaerobic respiration leading to lactic acid buildup as well as proton buildup from ATP 
hydrolysis (Xiong et al., 2008) and can remain for hours even after the blood supply is restored 
(Pignataro et al., 2007). This leads to neuronal death and brain injury through activation of 
ASIC1a. In a rat model of ischemia induced by middle cerebral artery occlusion (MCAO), 
inhibiting ASIC1a via intracerebroventricular injection of psalmatoxin-1 (PcTX), a specific 
ASIC1a inhibitor, reduced infarct volume by approximately 60% (Xiong et al., 2004). ASIC1 
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gene knockout has also been shown to provide neuroprotection following MCAO in rats (Xiong 
et al., 2004). Additionally, intracerebroventricular injection of sodium bicarbonate has also 
yielded neuroprotection, confirming that acidosis is triggering the cell death (Xiong et al., 2008). 
ASIC1a is an especially attractive target for preventing brain injury following ischemia because 
pathological acidosis is long lasting (Pignataro et al., 2007), and inhibiting ASIC1a even hours 
after the blood flow has been restored has been shown to prevent further injury (Pignataro et al., 
2007; Vergo et al., 2011). Thus, ASICs represent a potential therapeutic target within a clinically 
relevant time window.  
In addition to ischemic stroke, acidosis and ASICs play a role in a number of other 
conditions which foster brain damage. These include multiple sclerosis (Vergo et al., 2011), 
traumatic brain injury (Yin et al., 2013), retinal degeneration (Ettaiche et al., 2004), Parkinson’s 
disease (Ortega-Ramírez et al., 2017), and neurodegeneration in spinocerebellar ataxia (Vig et 
al., 2014). In a mouse model of multiple sclerosis, ASIC1 was shown to be upregulated in axons 
and oligodendrocytes, and axonal damage and demyelination were decreased by exposure to 
amiloride, an unspecific inhibitor of ASICs (Ortega-Ramírez et al., 2017). Additionally, in a 
mouse model of traumatic brain injury, neurodegeneration was lessened with bicarbonate 
administration as well as with knockout of the ASIC1a gene (Yin et al., 2013). Similarly, mice 
with ataxin-1 mutations associated with spinocerebellar ataxias have shown reduced disease 
phenotype with knockout of the ASIC1a gene (Ortega-Ramírez et al., 2017). Thus, ASIC1a is 
implicated widely in neurodegenerative conditions, and therapies targeting inhibition of ASIC-
mediated cell death in ischemic stroke may be useful tools capable of preventing injury in 
multiple other pathological conditions as well. 
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  ASICs represent a novel potential therapeutic target for neurodegeneration as well as 
brain damage following ischemic stroke. This is important as there are few effective therapeutics 
to limit brain damage following ischemic stroke. One strategy is the use of the recombinant 
tissue plasminogen activator (TPA), which works by breaking up arterial clots to restore blood 
flow to the brain. This strategy has yielded improved neurological outcomes in a large clinical 
trial (Schehr, 1996) and is used today. Unfortunately this approach ultimately has limited 
effectiveness in preventing permanent brain damage as it can be dangerous and highly increases 
patients’ risk of cerebral hemorrhage (Schehr, 1996). Thus, there are multiple exclusions for 
TPA intervention based on other morbidity factors, such as secured aneurysm or recent major 
surgery, as well as timing of arrival at emergency departments after stroke onset (Demaerschalk 
et al., 2016). Only an estimated 6-8% of stroke patients are even eligible to receive TPA therapy 
(Demaerschalk et al., 2016). Other neuroprotective strategies targeting distinct cell death 
pathways have been tried and failed to safely prevent permanent brain damage following an 
ischemic event. One strategy targeted voltage-gated calcium channels, but this too was 
ineffective in addition to causing negative cardiovascular side effects (Schehr, 1996). Similarly, 
the use of NMDA and AMPA antagonists have been tested in clinical trials but have also failed 
to provide effective neuroprotection and induced intolerable side effects such as hallucinations 
and cardiovascular effects (Schehr, 1996). However, inhibiting ASIC activity could reduce 
excitatory transmission without the side effects of NMDA antagonism, which would be 
consistent with the viability and fairly normal baseline synaptic transmission measured in ASIC 
knockout animals (Wemmie et al., 2002). ASICs represent an attractive target for 
neuroprotection following cerebral acidosis, however more work is needed to understand the 
mechanisms underlying ASIC-mediated cell death and ways ASICs can be regulated to alter 
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pathological activity. Further, a better understanding of interventions that might inhibit ASICs 
for therapeutic gain is needed before strategies targeting ASICs can be fully developed. 
Several ASIC inhibitors exist and are used to study ASIC activity, regulation, and 
neuroprotection. Amiloride acts as a diuretic which blocks sodium ion exchangers and the 
epithelial sodium channel (ENaC) as well as ASICs (Xiong et al., 2008). Amiloride is thought to 
inhibit ASIC activity by blocking the channel pore and was shown to reduce ASIC-mediated 
pain and ischemic neuronal death (Xiong et al., 2008). However, amiloride is not viable as an 
inhibitor of ASIC-mediated cell death in humans as its non-specificity leads to inhibition of ion 
exchange systems that are critical for survival (Xiong et al., 2008). Similarly, A-317567 is a non-
selective blocker of ASIC current at low doses that shows promise in alleviating ASIC-mediated 
chronic pain, although it minimally crosses the blood brain barrier and may affect the activity of 
vital ion exchange systems (Xiong et al., 2008). In addition to preventing prostaglandin 
production, non-steroid anti-inflammatory drugs (NSAIDS) have also been shown to inhibit 
ASIC activity and sensory neuron ASIC expression in inflammation, suggesting effectiveness of 
NSAIDS in the inhibition of painful conditions involving acidosis in the periphery, such as 
inflammation, infection, and blisters (Xiong et al., 2008). However, the concentration of 
NSAIDS required to inhibit ASIC activity is terrifically high and not viable to therapeutic 
intervention. Thus, there are no small molecule inhibitors of ASICs that can be used to 
specifically target ASIC activity in humans.  
One other strategy for ASIC inhibition relies on the use of venom peptides. Critically, 
certain peptides from venoms have shown to be useful tools in isolating ASIC activity and 
studying neuroprotection in ischemia. The peptide MitTx from the venom of the Texas coral 
snake acts as an ASIC agonist to induce pain (Bohlen et al., 2011), whereas mambalgins from 
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the venom of the black mamba snake (Diochot et al., 2012) and the peptide toxin APETx2 from 
the sea anemone (Xiong et al., 2008) block pain through ASIC inhibition. Psalmotoxin-1 
(PcTX), a peptide toxin from the venom of a South American tarantula, inhibits homomeric 
ASIC1a channels as a gating modifier with high specificity at nanomolar concentrations (Xiong 
et al., 2008). Intracerebroventricular injection of PcTX in animal models of ischemia has shown 
to be neuroprotective within a 5 hour time window (Xiong et al., 2008). However, PcTX may 
present problems in translation to human usage as its structure as a large peptide with three 
disulfide bonds makes it both difficult to synthesize and to cross the blood brain barrier (Xiong et 
al., 2008). Also the actions of PcTX with long term exposure are unclear. Its disulfide bonds may 
decrease stability due to sensitivity to oxidation and reduction (Xiong et al., 2008). There is also 
evidence from preliminary electrophysiology studies from the Askwith lab that long term 
exposure to PcTX enhances glutamatergic synaptic transmission and excitotoxicity. 
Additionally, the involvement of ASIC1a in important normal brain functions may compromise 
the advantages of this approach of complete ASIC inhibition to regulate ASIC-mediated 
neuronal death (Xiong et al., 2008). Overall, current ASIC inhibitors present problems and 
challenges in translation to human use in neuroprotection, and no strategies or treatments exist to 
specifically inhibit ASIC1a in patients. Identification of additional compounds and mechanisms 
targeting ASIC-mediated cell death inhibition are needed in order to develop an effective 
treatment to prevent debilitating brain injury following cerebral acidosis, potentially using 
existing therapeutics which may regulate ASIC activity. 
  Traditionally, the Askwith lab employs mechanisms to study ASIC involvement in cell 
death in the hopes that new strategies to target ASICs can be developed. The Askwith lab has 
mainly worked in tissue culture and whole animal studies. In cell culture, ASIC-mediated cell 
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death can be studied using assays exposing cells to a low pH solution (e.g. pH 6.0) versus a 
solution at physiological pH (pH 7.4). This approach has several advantages for conducting 
studies of the fundamentals of ASIC activity and cell death. For one, cells are all from one type 
of tissue or cell line (e.g. CHO cells or hippocampal neurons), so experiments are controlled to 
study the response of cells of interest. Additionally, cell growth and extracellular conditions are 
closely controlled, and ASIC activity can be easily isolated in a cell line lacking ASICs through 
ASIC transfection. However, drawbacks of this approach are that cells are removed from their 
native tissues so they lack natural cellular connections and have altered microenvironments when 
they are grown homogenously on a dish in cell culture media. Neurons cultured on a dish, for 
instance, lack interactions with other glial cells and neuron types that normally could be affecting 
their activity in the native brain environment. In addition, these tissues must come from neonatal 
animals. Further, acidosis solutions miss aspects of the conditions surrounding cells during 
cerebral deprivation of oxygen and glucose, and cells and slice cultures often must incubate for 
prolonged time periods before cell death can be measured. In contrast, whole animal studies 
leave native brain conditions and cellular connections for the most part intact. As a result, animal 
models of focal ischemia, such as middle cerebral artery occlusion, are useful to study actual 
effects in the mouse brain of ASIC inhibition. However, these models present challenges as 
individual factors, mechanisms, timing, and responses are more difficult to control and measure. 
Moreover, procedures are often invasive and technically highly challenging. Overall, a better 
system to study ASIC involvement in cell death eliminating some of these major challenges and 
bridging tissue culture and whole animal studies is needed. 
  One such system is the in vitro slice. The utilization of brain slices to study ASIC 
involvement in cell death has the advantages of maintaining many cellular connections and 
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conditions present in the native environment of the neurons under study in a controlled model 
that can be visualized. Although brain slices may exhibit increased sensitivity to ischemia and 
transcription of stress-related mRNA following the action of slicing (Lipton, 1999), slices 
represent valuable tools leading to in vivo studies as they maintain much of the cytoarchitecture 
of the brain and can be utilized without performing demanding brain surgery on live animals or 
introducing blood brain barrier and whole animal factors. Slice cultures are valuable tools 
normally used to study processes that occur over long periods of time as they can be maintained 
for months, whereas acute slices are widely used for short-term same-day electrophysiological 
studies (Lein et al., 2011). Specifically hippocampal slices have been widely used in 
electrophysiological studies following ischemia in oxygen-glucose deprivation (Lipton, 1999). 
Notably, slice cultures from rat brains were first used to quantify and study OGD induced cell 
death itself in 1995 by Strasser and Fischer (Strasser and Fischer, 1995). More recently, acute 
slices were shown to be useful tools in measuring ASIC-mediated cell death in oxygen-glucose 
deprivation (Bhowmick et al., 2017). Importantly, with the use of acute slices, cell death can be 
measured relatively immediately following the cell death event, and this cell death can be readily 
visualized. 
The acute brain slice subjected to oxygen-glucose deprivation represents a vital in vitro 
model to quantify ASIC-mediated cell death and explore neuroprotective interventions bridging 
cell culture and whole animal studies. In this thesis, I attempt to implement this in the Askwith 
lab through the development and optimization of an acute mouse brain slice model to quantify 
OGD-induced cell death mediated by acid-sensing ion channels. This model will provide 
increased replicability of the brain’s natural environment during cerebral acidosis compared to 
our neuronal culture studies. Finally, I will utilize this model to test novel therapeutics that 
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potentially inhibit ASIC activity and examine a molecular hypothesis on the mechanism of 
ASIC-mediated cell death. 
 
Chapter 2: Method Development 
Introduction 
The problem with targeting ASICs directly is that there are no existing therapeutics that 
function by directly inhibiting ASIC1a. Thus, testing the therapeutic potential of ASICs in 
humans has not yet been accomplished. The Askwith lab is focused on understanding how 
ASIC1a and acidotoxicity are regulated in order to determine whether strategies limiting ASIC-
induced toxicity could be developed from existing therapeutics. This regulation is studied in the 
lab using mainly neuronal cultures and electrophysiology. However the goal of the work covered 
in this chapter is to develop and optimize a method to quantify ASIC-medicated cell death in 
hippocampal slices subjected to oxygen-glucose deprivation (OGD), mimicking the conditions in 
the brain associated with cerebral ischemia. This will allow us to better mimic cerebral ischemia 
in an in vitro situation and provide a bridge between using neuronal culture and whole animal 
studies.  
Using this model, we can also add interventions of compounds of interest (Chapters 4 and 
5) and measure cell death to determine if a compound interacts with the ASIC-mediated cell 
death pathway to yield neuroprotection and to elucidate the mechanism of ASIC mediated cell 
death. The protocol development and optimization for the methods used to induce and quantify 
ASIC-mediated cell death in mouse hippocampal slices subjected to oxygen-glucose deprivation 





All experiments with vertebrate animals and animal protocols have been approved by the 
Institutional Animal Care and Use Committee at The Ohio State University. C57 black 6 male 
mice between the ages of 21-32 days from our transgenic mouse colony were sacrificed for use 
in this model. 
Solutions  
Cutting Solution: NaCl (125 mM), NaHCO3 (25 mM), NaH2PO4 (1.25 mM), KCl (3.5 mM), 
CaCl2 (0.1 mM), MgCl2 (3 mM), and Glucose (10 mM). Chilled on ice and bubbled with 95% O2 
5% CO2 for 45 minutes prior to use.  
Artificial Cerebrospinal Fluid (aCSF): NaCl (125 mM), NaHCO3 (25 mM), NaH2PO4 (1.25 
mM), KCl (3.5 mM), CaCl2 (2 mM), MgCl2 (1 mM), and Glucose (10 mM). Kept at room 
temperature and bubbled with 95% O2 5% CO2 for 45 minutes prior to use. 
Oxygen-Glucose Deprivation (OGD) Solution: NaCl (125 mM), NaHCO3 (25 mM), NaH2PO4 
(1.25 mM), KCl (3.5 mM), CaCl2 (2 mM), MgCl2 (1 mM), and Sucrose (10 mM). Kept at room 




Mice were anesthetized with isoflurane and immediately sacrificed by decapitation to obtain the 
fresh brain tissue. The brain was carefully dissected out, cut to separate the hemispheres, and 
positioned on a vibratome bathed in ice cold oxygenated cutting solution (Fig. 1). The vibratome 
blade was set to move at 0.14 mm/s and to cut the brain into 250 μm thick slices containing the 
hippocampus (n=6-8 slices from one animal). Following slicing, 
slices were transferred to a recovery solution to equilibrate for 60 
minutes in room temperature artificial cerebrospinal fluid rich in 
glucose and bubbled with 95% O2 5% CO2. Slices were held in 
uniquely designed holding chambers, crafted in 100-mL beakers 
with mesh near the bottom to gently hold slices and tubing to 
insert the oxygenation tube and create oxygen flow circulating 
through the solution. Each holding chamber contained 80 mL 
solution and up to four slices. It was experimentally determined 
that the optimal time from decapitation to the beginning of recovery was under 12 minutes in 
order to avoid excess cell death.  
 
Treatment 
Following recovery, slices were transferred to either a holding chamber containing glucose rich, 
oxygenated aCSF (control) or one containing solution mimicking cerebral oxygen-glucose 
deprivation with glucose replaced by sucrose and oxygen gas replaced by nitrogen gas. The 
slices were subjected to treatment/control for precisely 20 minutes. 





Following the period of 
oxygen-glucose deprivation or 
control, the slices were allowed 
to recover in aCSF once again 
containing glucose and oxygen 
for 60 minutes (Fig. 2). This reperfusion mimic was experimentally determined to aid in 
discrimination between the OGD-treated slices and the control slices in this model of ischemia as 
it allowed the OGD-exposed slices necessary time to carry out the cell death induced by the 20 
minute OGD treatment.  
 
Visualizing Cell Death 
Following the reperfusion mimic, the slices were exposed to TO-PRO®-3Iodide stain for 20 
minutes. We chose this far red stain as it labels dead cells by entering the dead cells through their 
compromised cell membranes and intercalating with their DNA (Fig. 3), causing dead cells to 
fluoresce under a confocal microscope. Following staining, slices were briefly rinsed in aCSF to 
wash off excess stain and then fixed in 4% paraformaldehyde shaking on a twelve well plate for 
Fig. 3. TO-PRO®-3Iodide Mechanism. Sta in enters dead cells through the compromised cell 
membrane and intercalates with DNA, allowing dead cells to be visualized by fluorescence 
in the far red spectrum. 
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60 minutes. Fixed slices were then mounted on microscope slides coated in Immuno Mount and 
allowed to cure for 45 minutes before imaging.  
A confocal microscope within the Department of Neuroscience was used to image the slices at 
the CA1 pyramidal cell layer of the hippocampus. It was experimentally determined that imaging 
the slices at a depth of 25 μm within the tissue was optimal for visualization of a stained, in-tact 
pyramidal cell layer and to discriminate between OGD-induced cell death and baseline cell death 





Cell death, represented by fluorescence in images taken using the confocal microscope, was 
quantified for OGD-exposed slices and control slices using histogram analysis through a 
program called FIJI. Thresholds were set for the intensity of fluorescence of pixels representing 
living and dead cells. These thresholds could be used to calculate the percentage of cell death 
within a specific area size of the pyramidal cell layer of the hippocampus in each brain slice. The 
average percent cell death for slices in the aCSF control group and slices in the OGD group were 
calculated, with n=1 for slices from one animal. 
Statistical significance was determined using standard methods in the field (shown in the graph 
descriptions), with a p value less than 0.05 indicating statistical significance. To compare two 
groups, we used an unpaired t-test when appropriate. When more than two groups were 
compared, a one-way ANOVA with Bonferroni Post Hoc analysis were used to determine 












With the procedure outlined above optimized for all conditions and variables, cell death data was 
collected using seven ASIC wildtype animals. Data from OGD-exposed slices from each animal 
were averaged, and data from control slices from each animal were averaged. Average percent 
cell death in slices exposed to oxygen-glucose deprivation and control slices was compared 
(Graph 1). Cell death was significantly lower in the aCSF control than in the OGD-exposed 
slices (p value=0.0026). These results indicate that this model can be used to both induce cell 
death by oxygen-glucose deprivation in mouse hippocampal slices and to quantify this cell death.  
Conclusion 
Data collected from the development and optimization of this model shows its usefulness as an 
in vitro model to study OGD-induced cell death and how it can be regulated. This model is a 
crucial bridge between studies in neuronal cultures and whole animal studies as it provides a way 
Graph 1. ASIC WT, OGD vs. Control. Wi ld type mouse hippocampal brain slices were exposed 
to oxygen-glucose deprivation (OGD) or control (aCSF).  Slices were imaged, and cell death 
was quantified using FIJI threshold histogram analysis.  One mouse counts as a sample, with 





to study cerebral acidosis in an in vitro situation which better mimics the native conditions 
within the brain during ischemia. Moving forward in this thesis, this model will be used with 
interventions of various compounds of interest from previous studies in the lab and from the 
literature to determine how the cell death measured using this model can be changed and 
regulated and to further elucidate a possible mechanism of ASIC-mediated death in cerebral 
ischemia. Importantly, in the next chapter, I will first discuss the ASIC1 specificity of this model 
determined by running trials with specific pharmacological ASIC1 inhibition as well as genetic 
knockout of the gene encoding the ASIC1 subunit. 
 
Chapter 3: Pharmacological Inhibition and ASIC1 KO 
Introduction 
Mice genetically lacking the ASIC1a subunit have shown deficits in pain, fear behaviors, 
and learning (Wemmie et al., 2002). Importantly, ASIC1a is the major ASIC subunit involved in 
ischemic neuronal death. Therefore, the OGD-induced cell death in our brain slice model of 
ischemic stroke can be tested for ASIC1 specificity by running trials of the experiment using 
ASIC1 KO mice and measuring cell death. The rationale for these studies is that, if cell death is 
equal in OGD-exposed slices and control slices in brain slices lacking the ASIC1 subunit, then 
there would be evidence that the cell death observed in this model is mediated by ASIC1. 
Similarly, measurements of cell death in brain slices exposed to oxygen-glucose 
deprivation in the presence of a pharmacological ASIC1 inhibitor are also useful to determine the 
specificity of this in vitro model to ASIC-mediated cell death. Specifically, we used a toxin, 
called Psalmotoxin-1 (PcTX), purified from the venom of a South American tarantula, 
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Psalmopoeus cambridgei (Escoubas et al., 2000). This toxin has been shown to inhibit 
homomeric ASIC1a channels with high specificity and affinity (Escoubas et al., 2000), making it 
a useful compound to help characterize the cell death pathways occurring in the OGD-induced 
cell death of our model. If cell death is reduced to basal levels in wildtype mouse brain slices 
exposed to oxygen-glucose deprivation with the ASIC1 inhibitor, PcTX, the observed cell death 
can be understood to be ASIC-mediated.  
Methods 
Pharmacological Inhibition 
The in vitro hippocampal slice model developed and described through Chapter 2 above was 
carried out following the same protocols for animals, solutions, slicing, recovery, treatments, 
reperfusion, staining, fixing, imaging, and quantification. The difference in these trials was that 
an intervention of PcTX was added acutely during the 20-minute OGD period. Because of this 
new treatment group, there were three groups of slice treatments: OGD, OGD plus PcTX (100 
nM), and an aCSF control. Slices were treated the same as in the model described in Chapter 2, 
and cell death was compared between each of the three treatment groups 
ASIC1 Knockout  
The model described in Chapter 2 was used in the same manner, except slices were obtained 




Decreased cell death was observed in OGD-exposed slices with acute administration of 
Psalmotoxin-1 (Graph 2). The average level of cell death in the OGD+PcTX group in the 
pyramidal cell layer of 
the hippocampus was 
reduced completely to the 
baseline level of cell 
death observed in the 
control group, while cell 
death in the OGD group 
was approximately twice 
as high (Fig 5).  
Graph 2. ASIC WT, OGD vs. OGD+PcTX vs. Control .  Wi ld type mouse 
hippocampal brain slices were exposed to oxygen-glucose deprivation (OGD), control 
(aCSF), or OGD+PcTX.  Slices were imaged, and cell death was quantified using FIJI 
threshold histogram analysis.  One mouse counts as a sample, with n=6. Bars 
represent hippocampal cell death averaged across the samples (one-way ANOVA p 
va lue=0.0076). Bonferroni’s Multiple Comparison test showed aCSF vs . OGD P <0.05, 





This was observed with slices from 
six animals (n=6, p value=0.0076) 
and 6-8 slices per animal. This 
suggests that the cell death being 
induced and quantified using this 
model is mediated by ASIC1. 
As expected, initial trials run with 
three ASIC1 KO mice showed no 
significant difference in levels of cell 
death between the OGD-exposed 
slices and control slices (p 
value=0.26, Graph 3). However, 
unexpectedly, basal cell death was 
increased in the control slices from 
the ASIC1 KO brain compared to 
basal cell death in the ASIC wildtype 
(p value=0.015, Graph 3). This 
increased level of cell death in the 
knockout mouse brain slice can be 
observed in the hippocampus of 
ASIC1 knockout mouse brain slices exposed to OGD or an aCSF control (Fig. 6). Basal cell 
death was significantly higher in the ASIC1 KO control than in the wildtype control, indicating a 
possible compensatory mechanism occurring in the ASIC1 knockout brain yielding excessive 
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chronic absence of 
the ASIC1 subunit. 
This compensation 
could be mediated by 
excess glutamate and 
excitoxicity in the 
absence of ASIC1. 
Graph 3. ASIC1 KO, OGD vs. Control. Knockout mouse hippocampal brain s lices were 
exposed to oxygen-glucose deprivation (OGD) or control (aCSF).  Slices were imaged, and 
cel l  death was quantified using FIJI threshold histogram analysis. One mouse counts as a  
sample, with n=3. Bars represent hippocampal cell death averaged across the samples (p 
value= 0.26). Wi ld type data is represented by dashed l ines, showing an increase in basal 




This hypothesis was tested by adding an intervention of the N-Methyl-D-aspartate (NMDA) 
receptor antagonist, MK801, to the recovery, treatment, and reperfusion mimic stages of both the 
OGD and control groups in our in vitro slice model with ASIC1 knockout mice. Additional cell 
death data was collected from ASIC1 knockout mouse hippocampal slices exposed to OGD, 
aCSF, OGD+MK801, or aCSF+MK801 (1 μM).  
With an increased sample size, cell death levels in ASIC1 KO slices were measured to be nearly 
identical following either OGD exposure or control (Graph 4), while still elevated above cell 
death levels seen in ASIC wildtype mice. With the addition of MK801, the NMDA antagonist, to 
the ASIC1 KO slices, we saw a trend of decreased cell death levels in the OGD-exposed slices as 
well as the control slices (Graph 4) to near the levels seen in the ASIC wildtype aCSF control. 
Graph 4. ASIC1 KO, OGD vs. aCSF vs. aCSF+MK801 vs. OGD+MK801. ASIC1 knockout 
mouse hippocampal brain slices (with and without exposure to the NMDA antagonist MK801) 
were exposed to oxygen-glucose deprivation (OGD) or control (aCSF).  Slices were imaged, and 
cel l  death was quantified using FIJI threshold histogram analysis. Bars represent hippocampal 
cel l  death averaged across the samples. One ASIC1 knockout mouse counts as a  sample 
(aCSF/OGD n=8, aCSF+MK801/OGD+MK801 n=2, OGD/OGD+MK801 n=1, aCSF/aCSF+MK801 
n=1). Significance was determined using one-way ANOVA (p va lue=0.37) and Bonferroni’s 
Multiple Comparison test (P >0.05 for comparisons of each group). No significant difference was 
found between any of the groups. Data was excluded here from one mouse brain sample 
exposed to aCSF/aCSF+MK801 as cell death from one slice was approximately 3 s tandard 




The result that cell death levels are approximately equal between aCSF and OGD treatment 
groups in either case in ASIC1 KO slices (p value >0.05) indicates that the OGD-induced cell 
death we are measuring with this model is ASIC1-mediated. Additionally, we see a trend of a 
decrease in cell death observed in the ASIC1 KO in the presence of MK801, although not 
statistically significant, (p value >0.05) suggesting that the enhanced basal cell death observed in 
the knockout hippocampus may be due, at least in part, to an NMDA-mediated increase in 
excitotoxicity in mice chronically lacking the ASIC1 subunit. 
Additionally, cell death data from one mouse (n=1) was excluded above (Graph 4) as the level 
of cell death measured in one single slice exposed to aCSF+MK801 was over 3 standard 
deviations from the mean. This excluded data can be viewed together with all of the ASIC1 
knockout data previously described (Graph 5). Besides the slice with cell death measured over 3 
Graph 5. ASIC1 KO, OGD vs. aCSF vs. aCSF+MK801 vs. OGD+MK801. Data point over 3 
standard deviations from the mean included. Bars  represent hippocampal cell death averaged 
across the samples. One ASIC1 knockout mouse counts as a  sample (aCSF/OGD n=8, 
aCSF+MK801/OGD+MK801 n=2, OGD/OGD+MK801 n=1, aCSF/aCSF+MK801 n=2). One-way 
ANOVA showed p va lue=0.63. Bonferroni’s Multiple Comparison test showed P >0.05 for 
comparisons of each group. Percent cell death in one single slice exposed to aCSF+MK801 was 
measured to be 46%, over 3 s tandard deviations from the mean. This data sample i s included 





standard deviations from the mean, all other hippocampal slices in the excluded mouse brain 
sample had cell death levels within 1 standard deviation of the mean. Therefore, it is possible 
that the outlier slice was damaged in the process of transfer between solutions as this data point 
differed so dramatically from the rest. However, slices in this specific brain sample exposed to 
aCSF+MK801 did show a trend of increased cell death relative to the cell death measured in the 
rest of the slices exposed to aCSF+MK801 (unpaired t-test p value=0.00043). Thus, error in this 
sample may be due to reagent degradation as this sample was from the last experiment run with 
the prepared MK801 solution, which is suspected to have gone through extra freeze-thaw cycles 
due to freezer malfunction. 
Conclusion 
The results of the experiments discussed in this chapter confirm that our in vitro model of 
ischemia, described in detail in Chapter 2, is inducing cell death mediated by ASIC1 with 
exposure to oxygen-glucose deprivation. This is significant as it shows that this model of 
cerebral ischemia can be used effectively as a tool to study the regulation of cell death mediated 
by ASIC1 and to help elucidate the mechanism of ASIC-mediated death by targeting different 
parts of the hypothesized pathway. Moving forward, and discussed in the next chapter, this 
model can be used with interventions of suspected neuroprotective compounds to determine how 
they impact OGD-induced cell death in an ASIC-dependent way. In addition to building on the 
fundamental understanding of ASIC-mediated cell death, these studies may one day lead to new 





Chapter 4: Neuroprotective Intervention: DOR Activation 
Introduction 
The Askwith lab has discovered that activation of the G-protein coupled receptor, delta 
opioid receptor (DOR), attenuates ASIC1a-induced acidotoxicity in cell culture models of acid-
induced neuronal death. Opioid receptors are commonly associated with the mu opioid receptor 
due to its well-known involvement in pain and drug addiction. However, there are two other 
opioid receptors, delta and kappa, whose functions are not as well defined. The delta opioid 
receptor (DOR) is abundantly expressed throughout the brain, and its activation has been shown 
to attenuate cell death in several experimental models, including ischemia (Chao et al., 2012; 
Charron et al., 2008; Kao et al., 2008; Oeltgen et al., 2006; Sherwood and Askwith, 2009). The 
Askwith lab found that DOR activation in neuronal culture acidosis assays reduced ASIC1a-
induced hippocampal neuronal death by 85%, suggesting that ASIC-induced neuronal death is 
central to DOR’s mechanism of action in ischemia. 
DOR agonists could be especially useful as a potential therapeutic for ASIC1a-induced 
brain injury as existing DOR agonists have already undergone clinical trials for major depressive 
disorder and anxiety (Hudzik et al., 2011; Pradhan et al., 2011). However, no clinical studies 
have tested the role of DOR-selective agonists in ischemia. The observation that DOR activation 
prevents ASIC1a-mediated injury would provide a molecular mechanisms for DOR-induced 
neuroprotection and suggest that DOR agonists target a novel mechanism of neuronal death 
(acidotoxicity) distinct from most strategies which have failed in clinical trials. Such a result 
could yield novel strategies to prevent neuronal death in humans and neurological injury in a 
variety of pathological conditions. 
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Interestingly, the Askwith lab has preliminary data that the mechanism of DOR-induced 
neuroprotection is unconventional. Using whole cell patch clamp neuronal analysis, the Askwith 
lab found that the DOR agonist, SNC80, does not alter the amplitude of the ion current or 
calcium influx of ASIC1a despite its preventative effects on ASIC-induced cell death. This 
suggests that DOR activation may prevent the toxic actions of ASIC1a, while leaving the 
physiological function of the channel untouched. This has large implications for possible 
treatments for ASIC-mediated cell death which prevent brain damage but allow the patient to 
retain normal ASIC functions. Thus, DOR activation may represent a novel strategy to target 
ASIC1a-induced cell death, offering therapeutic advantages if complete inhibition of ASIC1a 
function proves intolerable.  
Yet, DOR activation has only been shown to limit ASIC1a-induced neuronal death in 
culture models of acidotoxicity. The hypothesis of this chapter’s study is that DOR activation 
prevents ASIC1a-induced neuronal death following ischemic conditions in which acidosis is 
allowed to develop naturally. The goal of this chapter is to determine how the DOR agonist, 
SNC80, impacts ASIC1a-induced cell death in conditions similar to those following ischemic 
stroke using our OGD mouse brain slice model. The results of this work could help support 
therapeutics targeting DOR activation to prevent brain injury not only following stroke, but also 
other disorders involving ASIC1a-induced neuronal death, including multiple sclerosis (Vergo et 
al., 2011), traumatic brain injury (Yin et al., 2013), spinocerebellar ataxia (Vig et al., 2014), and 
retinal degeneration (Ettaiche et al., 2004). 
Methods 
The in vitro hippocampal slice model of ischemia developed and described through Chapter 2 
was carried out following the same protocols for animals, solutions, slicing, recovery, treatments, 
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reperfusion, staining, fixing, imaging, and quantification. The difference in these trials was that 
an intervention of SNC80 (a delta opioid receptor agonist) or DMSO was added acutely during 
the 20-minute OGD period. There were three groups of slice treatments: OGD plus SNC80 (1 
μM), OGD plus DMSO (same volume as SNC80), and an aCSF control. Slices were treated the 
same as in the model described in Chapter 2, and cell death was compared between each of the 
three treatment groups. 
Results 
By comparing average percent cell death levels between the aCSF control, the OGD+DMSO 
control, and the OGD+SNC80 treatment (Graph 6), a very similar picture to the PcTX data 
(Graph 2) was observed. Basal cell death and cell death resulting from DOR activation in the 
OGD+SNC80 treatment group were observed to be approximately half the average percent cell 
Graph 6. ASIC WT, OGD+DMSO vs. OGD+SNC80  vs. Control. Wi ld type mouse 
hippocampal brain slices were exposed to OGD+DMSO, OGD+SNC80, or control (aCSF).  Slices 
were imaged, and cell death was quantified using FIJI threshold histogram analysis.  One mouse 
counts  as a sample, with n=11. Bars represent hippocampal cell death averaged across the 
samples (one-way ANOVA p va lue= 0.000015). Bonferroni’s Multiple Comparison test showed 






death measured in the OGD+DMSO group of slices (Fig 7). These data were collected with 11 
ASIC wildtype mice (n=11, p value=0.000015). 
 
Conclusion 
Reduction of cell death to basal levels in the mouse hippocampal slices exposed to oxygen-
glucose deprivation with delta opioid receptor activation suggests that the activation of DOR 
may be neuroprotective in cerebral ischemia. As cell death is reduced to basal levels with DOR 
activation as with the addition of PcTX in OGD-exposed slices, this suggests that DOR is acting 
on an ASIC1-dependent pathway to induce neuroprotection. This implicates existing DOR 
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agonists as novel therapeutics for ischemic stroke and other neurological disorders through the 
inhibition of ASIC1-dependent cell death. To further elucidate the mechanism of this ASIC-
mediated cell death pathway and how DOR could be exerting its neuroprotective benefits, the 
impact of Receptor Interacting Protein Kinase 1 (RIP1) inhibition on ASIC-mediated cell death 
in this model was tested. This is discussed in detail and is the main focus of the next chapter. 
 
Chapter 5: Mechanistic Component: RIP1 Inhibition 
Introduction 
There is strong evidence for the involvement of the Receptor Interacting Protein Kinase 1 
(RIP1) in the ASIC-mediated cell death pathway under study. Extracellular protons induce a 
conformational change in the ASIC1 protein independent of the channel pore. Recent studies 
have found that in acidic conditions, RIP1 binds to the ASIC1a C-terminus, which leads to RIP1 
phosphorylation and subsequent cell death through a type of organized necrosis-like process 
called necroptosis (Wang et al., 2015). This protein-protein association and cell death was 
detected in affected mouse brain areas in a middle cerebral artery occlusion model of ischemia 
and was found to be prevented in ASIC1 KO animals (Wang et al., 2015). Necroptosis in 
neurons was found to be inhibited by intervention of necrostatin-1 (nec1), a RIP1 inhibitor 
(Wang et al., 2015). Moreover, acid-evoked neuronal death was similarly inhibited by both 
PcTX and nec1 (Wang et al., 2015). This suggests that inhibiting the activity of RIP1 with 
necrostatin-1 prevents ASIC-dependent acid-induced death. As RIP1 is not phosphorylated in the 
presence of PcTX and acid, ASIC1a must be needed for the phosphorylation to occur. 
Additionally, ASIC1a knockout mouse brains do not exhibit RIP1 phosphorylation following 
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acidosis in ischemic stroke. This implicates a connection between ASIC1a and RIP1 in this 
process. Understanding this connection would elucidate the mechanism of ASIC-mediated death 
and provide a better understanding of interventions targeting acidotoxicity.  
Another important aspect of research on this topic is the timing of the mechanism. 
Studies found that the addition of nec1 in neuronal cultures was only effective at reducing cell 
death if it was administered before the acid exposure as well as during the exposure (Wang et al., 
2015). Additionally, within 30 minutes of acidosis, the amount of RIP1 protein increases but 
then decreased below its basal levels by 60 minutes (Wang et al., 2015). This timing factor is 
important to consider in the study of the impact of RIP1 inhibition on ASIC-mediated cell death 
in our mouse brain slice model. Additionally, RIP1 was found to physically associate with 
ASIC1a within 30 minutes of ischemia and remains associated for hours (Wang et al., 2015). 
This supports the importance of the ASIC1-RIP1 interaction in acid-induced neuronal death as 
acidosis resulting from ischemia lasts for a long time and spreads slowly, leading to delayed 
ischemic brain injury. This aspect of brain injury is important to study to prevent extensive 
damage following stroke. 
Interestingly, according to recent studies, ASIC current was suggested to be ruled out in 
the mechanism for ASIC-mediated acid-induced cell death (Wang et al., 2015). With exposure to 
acidic conditions, homomeric ASIC1a channels become desensitized quickly with low Ca2+ 
permeability (Wang et al., 2015). As most brain acidosis occurs slowly, ASIC-mediated Ca2+ 
influx would be relatively small and not likely to be the cause of major cell death (Wang et al., 
2015). Additionally, PcTX and nec1 have been found to inhibit death in neuronal cultures 
exposed to acidic conditions even without Ca2+ present (Wang et al., 2015). Further, desensitized 
ASIC1a is still able to induce cell death (Wang et al., 2015). Importantly, this cell death may 
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involve an ASIC1-RIP1 protein interaction independent of ASIC1 current, suggesting that 
treatments could be developed to target the pathological functions of ASIC1a while leaving 
critical physiological functions intact. 
To study this novel hypothesis on the molecular mechanism of ASIC-mediated cell death 
and to begin to potentially determine a route through which delta opioid receptor activation is 
neuroprotective, our in vitro slice model described in detail in Chapter 2 can be utilized with an 
intervention of necrostatin-1, a RIP1 inhibitor. The timing and impact of nec1 action on OGD-
induced cell death in this model will help to elucidate the involvement of RIP1 in ASIC-
mediated ischemic neuronal death and also explore RIP1 inhibition as a target for the 
neuroprotective regulation of ASIC-mediated cell death.  
Methods 
Pre/concurrent Incubation with RIP1 Inhibitor 
The in vitro hippocampal slice model developed and described in Chapter 2 was used following 
the same protocols for animals, solutions, slicing, recovery, treatments, reperfusion, staining, 
fixing, imaging, and quantification. The difference in these trials was that an intervention of 
necrostatin-1 (nec1), a RIP1 inhibitor, or DMSO was added during the last 20 minutes of 
recovery after slicing as well as during the 20-minute OGD period to allow for pre incubation as 
well as concurrent incubation with the ischemic event. In addition to these treatments, control 
slices were exposed to aCSF alone. There were three groups of slice treatments: OGD+nec1 (20 
uM), OGD+DMSO (same volume as nec1) and an aCSF control. Slices were treated the same as 




Acute (concurrent) Incubation with RIP1 Inhibitor 
The same procedure was followed as above, except slices were exposed to nec1 or DMSO only 
during the OGD period with no pre-incubation.  
Results 
Comparing average percent cell death between slices exposed to OGD+nec1, OGD+DMSO, and 
aCSF with the 20 minute pre-incubation period showed a significant difference in cell death 
levels (n=6, p value=0.00020), with a decrease in cell death in the OGD slices exposed to nec1 to 
basal levels measured in the aCSF control (Graph 7). Average percent cell death observed in the 
OGD+DMSO group was approximately twice as high as the average percent cell death measured 
in the control slices as well as in the slices exposed to OGD with necrostatin-1 (Fig. 8). 
Graph 7. ASIC WT, OGD+DMSO vs. OGD+Necrostatin-1 vs. Control. Wild type mouse 
hippocampal brain slices were exposed to 20 minutes pre-incubation of nec1, DMSO, or 
control , followed by 20 minutes of OGD+DMSO, OGD+nec1, or control (aCSF).  Slices were 
imaged, and cell death was quantified using FIJI threshold histogram analysis.  One mouse 
counts  as a sample, with n=6. Bars represent hippocampal cell death averaged across the 
samples (one-way ANOVA p va lue=0.00020). Bonferroni’s Multiple Comparison test showed 






With acute nec1 administration, or inhibition of RIP1 only during the OGD period, average 
percent cell death levels were approximately equal between the slices exposed to OGD+nec1 and 
those exposed to OGD+DMSO, but lower in the aCSF control (Graph 8, p value=0.0079). This 
Graph 8. ASIC WT, Acute OGD+DMSO vs. Acute OGD+Necrostatin-1 vs. Control. Wild type mouse 
hippocampal brain slices were acutely exposed to 20 minutes of OGD+DMSO, OGD+nec1, or control (aCSF) 
with no pre-incubation period.  Slices were imaged, and cell death was quantified using FIJI threshold 
his togram analysis.  One mouse counts as a  sample, with n=6. Bars represent hippocampal cell death 
averaged across the samples (one-way ANOVA p va lue=0.0079). Bonferroni’s Multiple Comparison test 





shows that necrostatin-1 must be administered prior to the oxygen-glucose deprivation event in 
order to interfere effectively with this ASIC-mediated cell death pathway.  
Conclusion 
Reduction of cell death to basal levels in slices exposed to oxygen-glucose deprivation with 
necrostatin-1 suggests that the observed ASIC-mediated cell death is dependent on RIP1 activity. 
Involvement of RIP1 in ASIC-mediated cell death induced in this in vitro model suggests that 
RIP1 may be a key player in neuronal death in cerebral acidosis as a result of ischemic stroke. A 
possible mechanism for neuronal death following ischemic stroke could be an extracellular 
proton-induced conformational change in the ASIC1a protein leading to RIP1 association at the 
ASIC1a C-terminus and RIP1 phosphorylation, ultimately leading to necroptosis of the neurons.  
The result that ASIC-mediated cell death was not attenuated by inhibition of RIP1 activity during 
the OGD period alone without necrostatin-1 pre-incubation suggests that inhibiting RIP1 activity 
with necrostatin-1 is not an effective therapeutic strategy for attenuating brain damage following 
an ischemic stroke. Evidence from this model indicates that inhibition would have to occur prior 
to the ischemic event, which is not a practical time frame to prevent brain damage. The 
knowledge gained from these experiments is useful moving forward in elucidating the 
mechanism of ASIC-mediated cell death regulation. 
 
Chapter 6: Discussion 
First, in this thesis, I developed a mouse hippocampal acute slice model of ischemia to 
study neuronal death in oxygen-glucose deprivation. Similarly to other models of ischemia 
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(Bhowmick et al., 2017; Xiong et al., 2004; Yang et al. 2011), the cell death in our acute slice 
model was shown to be mediated by ASIC1a and was prevented by the specific ASIC1a 
inhibitor, psalmotoxin-1. Additionally, cell death induced by OGD conditions was reduced 
relative to the control in the ASIC1 knockout mouse. Second, I used this model to measure the 
effect of activation of the delta opioid receptor on ASIC-mediated cell death and found 
attenuation of OGD-induced death. This result replicated our data in neuronal culture and is 
consistent with previous studies showing attenuation of cell death in ischemia through DOR 
activation (Chao et al., 2012; Charron et al., 2008; Kao et al., 2008; Oeltgen et al., 2006). A third 
piece to this study looked to the novel mechanism of this cell death by investigating involvement 
of the Receptor Interacting Protein Kinase 1 in OGD-induced cell death mediated by ASIC1a. 
Attenuation of cell death was observed with inhibition of RIP1 activity, a result that is consistent 
with previous evidence of RIP1 involvement in ASIC-mediated neuronal death (Wang et al., 
2015).  
The result that RIP1 plays a role in ASIC-mediated cell death in this model has large 
implications. Studies indicating that ASIC pathological activity is RIP1 dependent show that this 
ASIC-mediated cell death occurs independent of ASIC current (Wang et al., 2015). Targeting 
this activity could interfere with ASIC-mediated cell death following an ischemic stroke in a 
novel, therapeutically meaningful way as cell death inhibition may not interfere with normal 
ASIC function. Specifically, neuroprotection as a result of activation of the delta opioid receptor 
may be through the interruption of a part of this RIP1-dependent pathway. This would be 
consistent with findings in the Askwith lab that DOR activation does not interfere with ASIC 
current. Importantly, this suggests that potentially RIP1-dependent DOR activation in patients 
following an ischemic stroke could prove to be a valuable strategy to protect the brain from 
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permanent injury induced by 
pathological ASIC activity 
while leaving important normal 
ASIC functions intact (Fig. 9). 
The neuroprotection observed 
in hippocampal oxygen-
glucose deprivation with DOR 
activation in this model 
suggests that existing DOR agonists, which have already undergone clinical trials for major 
depressive disorder and anxiety (Hudzik et al., 2011; Pradhan et al., 2011), may prove to be 
effective in attenuating brain damage following an ischemic stroke in patients.  
This potentially neuroprotective benefit of DOR activation following an ischemic stroke 
is supported by other studies looking at DOR expression in certain animals. Specifically, animals 
that undergo hibernation are particularly resistant to decreased oxygen and blood flow during the 
hibernation period (Johnson and Turner, 2010). Interestingly, studies showed that injecting a 
DOR agonist intravenously into summer active ground squirrels activated hibernation, and 
injecting plasma from hibernating woodchucks into mice before inducing focal ischemia was 
neuroprotective (Johnson and Turner, 2010). Additionally, red-eared slider turtles, which are 
able to hold their breath for up to 48 hours, exhibit higher levels of DOR expression in the brain 
than rats, which may contribute to resistance to hypoxia (Johnson and Turner, 2010). Our results 
are consistent with these observations of DOR-induced resistance to hypoxia and show that DOR 
activation attenuates ASIC-mediated hippocampal death following oxygen-glucose deprivation 




ASIC-mediated cell death in oxygen-glucose deprivation is dependent on RIP1, which is 
significant as the mechanism of DOR-induced neuroprotection is not fully understood (Staples et 
al., 2013). This DOR-induced neuroprotection may be through a novel RIP1-dependent 
mechanism involving disruption of ASIC1-RIP1 protein associations or RIP1 phosphorylation. 
Our results lay the framework for further investigation into this mechanism to better understand 
the exact action of DOR in neuroprotection and to potentially develop new therapeutics for 
ischemic stroke targeting DOR activation. 
Further, the result that DOR activation attenuated neuronal death during the OGD period 
alone without agonist pre-incubation is therapeutically promising. In contrast, inhibition of RIP1 
activity during OGD alone failed to attenuate cell death. One possibility is that DOR may be 
interfering with a later step in the proposed cell death pathway. However, this effect is likely a 
result of the longer time period needed for necrostatin-1 to enter the cell and reach its target 
intracellularly. In contrast, SNC80 reaches its target more quickly to inhibit ASIC-mediated cell 
death as DOR is a G-protein coupled receptor located in the cell membrane. Therefore, targeting 
DOR activation may prove to be an effective strategy to inhibit RIP1-dependent ASIC-mediated 
neuronal death within a clinically relevant time window. Further, it has been shown that 
inhibiting ASIC1a even hours after blood flow has been restored stops further injury from 
occurring (Pignataro et al., 2007; Vergo et al., 2011). DOR activation may interfere with RIP1-
dependent ASIC-mediated cell death in such a way, representing a clinically viable therapeutic 
target. More work should be done to look at the specific timing of DOR activation in 
neuroprotection in the context of ASIC-mediated ischemic cell death as well as the exact 
mechanism of DOR interference in this RIP1-dependent cell death to further elucidate the 
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